Biogen may sue third generic drug maker to protect MS drug Tecfidera

Intellectual Property 2021-12-10 4:14 pm | Melbourne
Swiss pharmaceutical company Biogen is considering a third patent infringement lawsuit against a drug maker to shield its monopoly in Australia for blockbuster multiple sclerosis drug Tecfidera from generic competition.
For information on rights and reprints, contact subscriptions@lawyerly.com.au